Wall Street woke up to a rare sight this week: peptides moving out of the regulatory penalty box and straight into the growth-stock conversation. Hims & Hers Health Inc. (NYSE: HIMS) extended its recent rally after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. signaled that the Food and Drug Administration is preparing to ease limits on a slate of popular peptide treatments. For a market that has spent the last two years pricing in ever-tighter rules on compounding and wellness therapies, the tone suddenly sounds much more like opportunity than overhang.
At the same time, a quieter but equally important regulatory win landed in diabetes tech: Modular Medical Inc. (NASDAQ: MODD) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, opening the door to commercial sales in the U.S. as early as the end of the second quarter. One headline points to a potential re-rating of the telehealth and wellness complex; the other underscores how regulatory milestones can still create genuine product-driven upside in a crowded medical device field.
RFK Jr., Peptides, And The New Regulatory Mood Music
For peptide watchers, RFK Jr.’s latest comments were more than just podcast fodder. He has said that roughly 14 of 19 peptides previously parked on the FDA’s “do not compound” list could be moved back into a category that allows licensed compounding pharmacies to prepare them for patients with prescriptions. The FDA, for its part, has signaled it will hold an advisory committee meeting this summer to consider easing restrictions on at least seven peptide injections, including buzzy names like BPC-157, which have become staples among wellness influencers and fitness personalities.
The agency is not exactly throwing a peptide party: officials continue to stress that many of these therapies lack robust safety data and have never gone through the full drug-approval process. But the shift from outright prohibition toward a more calibrated, risk-based framework suggests that regulators are open to a middle path that doesn’t strand patients—or the companies serving them—between black-market imports and fully approved biologics. For investors, that nuance matters: the conversation is evolving from “if” to “how fast” and “how wide” any loosening will run.
Why Hims & Hers (HIMS) Suddenly Looks Less Hemmed In
Few companies are more levered to the peptide and compounding narrative than Hims & Hers Health (HIMS), the telehealth platform that has turned branded wellness into something resembling a consumer subscription business. The company’s explosive growth over the last several years has been tied in no small part to its expansion into injectable weight-loss treatments, including compounded alternatives to headline GLP‑1 brands. That success also brought heightened scrutiny, culminating in a series of regulatory questions around compounding practices and an aborted attempt to launch a compounded GLP‑1 pill that accelerated pressure on both the company and the broader compounding sector.
Heading into 2026, analysts were increasingly focused on whether Hims & Hers could diversify fast enough to offset any “draconian scenario” for compounded GLP‑1s in the U.S. Management has emphasized the breadth of its portfolio—from mental health to men’s health and hormone therapies—but the market has largely viewed the stock through a weight-loss lens, rewarding growth while worrying about regulatory whiplash. Against that backdrop, signs that the FDA may ease restrictions on key peptides—and that RFK Jr. is inclined to push for more permissive compounding rules—sound like the first favorable tailwind HIMS has seen from Washington in some time.
Investors are now gaming out a scenario in which Hims & Hers can maintain momentum in its high-demand metabolic and performance categories without the same binary fear of a regulatory rug pull. The company still faces the hard work of balancing safety, compliance, and growth, but the immediate takeaway is simple enough for Wall Street: a regulatory overhang that once looked like an anchor now resembles a kite with a bit of wind behind it.
Peptides, GLP‑1s, And The Telehealth Growth Equation
The peptide conversation does not happen in isolation; it sits on top of a broader debate about the durability of the GLP‑1 and metabolic-health boom. Hims & Hers has reported rapid subscriber and revenue growth as it leaned into injectable weight-loss medicines starting in 2024, with investor expectations that annual sales would climb into the multi‑billion‑dollar range by 2025. Yet Wall Street has been equally quick to question how sustainable those trends are when regulatory attitudes toward compounding can shift faster than consumer demand curves.
Potential easing on peptides may offer an incremental release valve—allowing platforms like Hims & Hers to offer a broader toolkit of therapies under a clearer set of rules, rather than operating in a constant state of regulatory improvisation. It also underscores a broader structural shift: telehealth is no longer just about convenient access to generics; it is becoming a distribution channel for more specialized, protocol-driven regimens that depend on regulators, pharmacies, and digital platforms playing reasonably well together. If that ecosystem stabilizes, HIMS could find itself less at the mercy of single‑product narratives and more able to cultivate recurring, diversified revenue streams across men’s health, mental health, dermatology, and metabolic care.
Of course, “less at the mercy” doesn’t mean “free from risk.” As the FDA convenes experts to weigh safety issues—from potential cancer risks to organ toxicity—the peptide space remains very much a work in progress. But from the vantage point of equity markets, the direction of travel has shifted just enough to reprice optimism, especially for platforms like Hims & Hers that have already demonstrated an ability to turn regulatory clarity into subscriber growth.
Modular Medical (MODD) And A Pivotal Moment In Diabetes Tech
While peptide headlines capture the imagination, a very tangible device win is unfolding in diabetes care. Modular Medical (MODD) has received FDA 510(k) clearance for its Pivot tubeless insulin patch pump, a milestone that moves the company from “story stock” to “commercial execution story” almost overnight. Pivot is built as a two‑part, removable patch system with a 3 mL reservoir, a disposable battery, and smartphone connectivity for bolus dosing and monitoring—features designed to reduce complexity and cost, two of the biggest barriers preventing millions of insulin‑dependent patients from adopting pump therapy.
Management expects initial shipments to begin by the end of the second quarter of 2026, clearing a near‑term catalyst path that many small‑cap med‑tech names lack. CEO Jeb Besser has framed the clearance as both a validation of years of engineering work and a de‑risking event that paves the way for future software upgrades, including automated insulin delivery features. That roadmap positions MODD to compete in what it views as a multi‑billion‑dollar “almost‑pump” market segment: patients who remain on injections not because they dislike technology, but because existing pumps are too bulky, too complex, or too expensive.
For investors, Pivot’s approval offers a reminder that not all healthcare upside needs to flow through the GLP‑1 channel. As blockbuster weight‑loss drugs reshape obesity and diabetes treatment, simpler, more user‑friendly insulin delivery platforms can still carve out meaningful share by addressing quotidian frictions in daily care. In a market often obsessed with miracle molecules, a modestly priced, removable patch that fits better into a patient’s life can be a surprisingly powerful growth engine.
A Market Leaning Into Regulated Optimism
The week’s regulatory developments—RFK Jr.’s peptide signaling and Modular Medical’s (NASDAQ: MODD) FDA green light—offer a useful snapshot of where healthcare investing sits in 2026: somewhere between risk management and renewed optimism. For Hims & Hers (HIMS), looser peptide rules could ease a major overhang and bolster confidence that its model can adapt as regulators refine rather than outright reject compounding‑based care. For Modular Medical (MODD), a straightforward device clearance underscores that disciplined innovation and regulatory execution still get rewarded, even in the shadow of headline‑grabbing therapies.
Investors will now watch whether talk turns into text: FDA guidance, AdCom outcomes, and the first real‑world Pivot users will provide the next set of data points to either support or temper the current enthusiasm. For now, though, the message from Wall Street is clear enough: when regulators open a door—even just a crack—capital is more than willing to walk through it, prescription pad and insulin patch in hand.
Tribe Public CEO Presentation and Q&A Event
Vista Partners sister organization, Tribe Public (www.TribePublic.com) is seeking to add a Tribe Public CEO Presentation and Q&A Webinar-based Event soon to cover Modulator Medical and Hims & Hers’ and other companies and other subjects soon. Please add them to your wishlist today at Tribe Public’s website Wish list area at this link.
